Introduction {#s1}
============

During development, neural specification leads to the emergence of a large diversity of neuronal subtypes that will serve distinct functions in the adult nervous system. A key issue concerns the nature and action of the molecular cues underlying the acquisition of both generic and specific characteristics of neurons. A small number of basic helix-loop-helix (bHLH) transcription factors are necessary and sufficient for progenitor cell commitment towards a neuronal lineage at the expense of a glial fate and have consequently been qualified as "proneural genes" [@pone.0092113-Bertrand1]. Beside their generic function, several studies have shown that proneural genes also display context-dependent effects contributing to the differentiation of particular neuronal subtypes [@pone.0092113-Bertrand1], [@pone.0092113-Powell1]. This is the case for the *atonal-related neurogenin* genes (*Neurog1* and *Neurog2*) and the *achaete scute* gene *Ascl1* (*achaete-scute complex homolog 1*; also called *Mash1* in mouse or *Xash1* in *Xenopus*). These genes are mostly expressed in complementary patterns in the murine central and peripheral nervous system where they drive the production of distinct neuronal populations [@pone.0092113-Brzezinski1], [@pone.0092113-Fode1], [@pone.0092113-Osorio1], [@pone.0092113-Parras1]; reviewed in [@pone.0092113-Bertrand1], [@pone.0092113-Schuurmans1], [@pone.0092113-Wilkinson1]. In particular, *Neurog2* and *Ascl1* appear respectively as key regulators of glutamatergic (excitatory) *versus* GABAergic (inhibitory) neuronal fates during telencephalic development [@pone.0092113-Fode1], [@pone.0092113-Parras1], [@pone.0092113-Casarosa1], [@pone.0092113-Jo1], [@pone.0092113-Schuurmans2], [@pone.0092113-Wilson1]. The implication and requirement of *Ascl1* in GABAergic cell specification has however proved to be highly time and space dependent [@pone.0092113-Jo1], [@pone.0092113-Peltopuro1], [@pone.0092113-Mizuguchi1]. In addition, *Ascl1* is also involved in the development of other neuronal subtypes such as hindbrain serotonergic neurons [@pone.0092113-Pattyn1], [@pone.0092113-Jacob1], central and peripheral noradrenergic neurons [@pone.0092113-Goridis1], [@pone.0092113-Hirsch1], [@pone.0092113-Howard1] or mesencephalic dopaminergic neurons [@pone.0092113-Park1]. Exploring its involvement in other nervous system regions, such as the retina, and unravelling how it integrates within distinct genetic networks are now required to better understand its divergent properties.

In the retina, beside its proneural function [@pone.0092113-Nelson1], [@pone.0092113-Tomita1], [@pone.0092113-Tomita2], *Ascl1* may also have a more specialized role in the commitment of particular cell subtypes since its expression is restricted to subsets of neuronal progenitors, mostly distinct here again from the *Neurog2*-expressing ones [@pone.0092113-Brzezinski1], [@pone.0092113-Jasoni1], [@pone.0092113-Jasoni2], [@pone.0092113-Marquardt1]. If numerous studies have addressed the intrinsic mechanisms responsible for the generation of the diverse classes of retinal neurons such as photoreceptor or ganglion cells [@pone.0092113-Agathocleous1], [@pone.0092113-Hatakeyama1], [@pone.0092113-Ohsawa1], studies reporting on the molecular cues governing the specification of retinal subtypes with a specific neurotransmitter phenotype remain sparse [@pone.0092113-Ohsawa1], [@pone.0092113-Adler1], [@pone.0092113-Feng1], [@pone.0092113-Mo1], [@pone.0092113-Suga1], [@pone.0092113-Zaghloul1]. As in the brain, GABAergic and glutamatergic neurons represent the most abundant inhibitory and excitatory neurons of the retina, respectively. They are distributed among the 6 major classes of retinal neurons: photoreceptor, bipolar and ganglion cells are mainly glutamatergic, whereas most GABAergic retinal neurons are found within amacrine and horizontal cells. Only a few factors, such as the bHLH transcription factor BHLHB5 [@pone.0092113-Feng2], the cofactor LMO4 [@pone.0092113-Duquette1], the orphan nuclear receptor Nr4a2 [@pone.0092113-Jiang1] or the PACAP receptor PAC1 [@pone.0092113-Lang1] have so far been involved in GABAergic amacrine cell production in the retina.

Our previous studies and others highlighted that the bHLH gene *Ptf1a* (*pancreas transcription factor 1a*), drives inhibitory neuron commitment in the retina, at the expense of a glutamatergic destiny [@pone.0092113-Dullin1], [@pone.0092113-Fujitani1], [@pone.0092113-Jusuf1], [@pone.0092113-Lelievre1], [@pone.0092113-Nakhai1]. However, upstream regulators, partners and targets of *Ptf1a* within the retina remain to be investigated. Considering the GABAergic instructive function of *Ascl1* in various regions of the brain, and the fact that *Ptf1a* expression is decreased in the dorsal spinal cord and retina of *Ascl1^−/−^* mice [@pone.0092113-Mizuguchi1], [@pone.0092113-Nelson1], we asked whether it could be required for retinal GABAergic cell specification and whether it could take part to the *Ptf1a* transcriptional network.

To address these issues, we first analysed *Ascl1* function during *Xenopus* retinogenesis. We found that *Ascl1* is required for GABAergic retinal neuron genesis and sufficient to bias a subset of retinal progenitors towards a GABAergic destiny. Then, we took advantage of the *Xenopus* ectopic neurogenesis induction paradigm to investigate which genetic interactions contribute to Ascl1 activity as an inducer of neurotransmitter phenotypes. We showed that distinct *Ascl1*-dependent transcriptional networks sustain the production of GABAergic and catecholaminergic neurons. Together, our data suggest that the GABAergic activity of Ascl1 requires *Ptf1a*, this latter being a direct transcriptional target of Ascl1.

Materials and Methods {#s2}
=====================

Constructs {#s2a}
----------

pCS2-Ascl1 (also called Xash1 [@pone.0092113-Ferreiro1]), pCS2-Ptf1a, pCS2-Ptf1a-GR [@pone.0092113-Afelik1], pCS2-XNeurog2 (also called XNgnr-1), pCS2-Neurog2-GR [@pone.0092113-Perron1], pCS2-Atoh7 (also called Xath5 [@pone.0092113-Kanekar1]), pCS2-NeuroD1 (also called NeuroD [@pone.0092113-Chitnis1]), pCS2-GFP [@pone.0092113-Chalfie1] and all glucocorticoid-inducible chimeric Ascl1:Neurog2 constructs [@pone.0092113-Talikka1] have previously been described. pCS2-flag-Ascl1-GR was generated by subcloning the Ascl1 coding sequence from pCS2-NLSMT plasmid into EcoRI and XhoI sites of pCS2-flag-GR [@pone.0092113-Gammill1]. Protein activity of GR constructs was induced by addition of 4 μg/ml dexamethasone (dex, Sigma).

Embryos, *in vitro* RNA synthesis and microinjection {#s2b}
----------------------------------------------------

*Xenopus laevis* embryos (up to stage 41) were obtained by conventional procedures of *in vitro* fertilization and staged according to Nieuwkoop and Faber [@pone.0092113-Nieuwkoop1]. At the desired stage, embryos were fixed in 4% paraformaldehyde. Capped sense mRNAs were prepared from CS2 plasmids after Not1 digestion and transcribed using the mMessage mMachine SP6 kit (Ambion). mRNAs were then purified with Sephadex Column (Roche). 100--150 pg of mRNAs were injected into one or two blastomeres at the two- or four-cell stage. *GFP* mRNA was co-injected as a tracer. Loss of function experiments were performed using already described and validated antisense oligonucleotides morpholinos: *Ptf1a*-Mo [@pone.0092113-Dullin1], *Ascl1*-Mo (a mix of two morpholinos, *Ascl1*-Mo1 and *Ascl1*-Mo2, that target the two *Xenopus laevis Ascl1* alloalleles; [@pone.0092113-Parlier1]), *Phox2a*-Mo and *Hand2*-Mo [@pone.0092113-Parlier1]. As a control, standard morpholinos purchased from GeneTools (LLC) were used. 8 ng of morpholinos were injected into one or two blastomeres at the two-cell stage. All embryos were co-injected with *GFP* mRNA as a tracer and only embryos exhibiting GFP fluorescence in the eye were selected for further analysis.

*In vivo* lipofection {#s2c}
---------------------

*pCS2-Ascl1, pCS2-Neurog2, pCS2-Atoh7*, *pCS2-NeuroD1* were transfected in stage 18 neurula into the presumptive region of the retina as previously described [@pone.0092113-Holt1], [@pone.0092113-Ohnuma1]. *pCS2-GFP* was co-lipofected and used as a tracer to follow transfected cells. Of note, co-lipofection efficiency was previously shown to be extremely high (85%--100%) [@pone.0092113-Holt1]. Embryos were fixed at stage 41 in 4% paraformaldehyde plus 0,3% glutaraldehyde and cryostat sectioned (12 μm). Transfected cells were counted and cell types were identified based upon their laminar position and morphology.

Immunohistochemistry {#s2d}
--------------------

Immunohistochemistry was performed using rabbit polyclonal anti-GABA (1/1000; ImmunoStar), mouse monoclonal anti-GFP (1/200; Molecular Probes) and anti-mouse or anti-rabbit fluorescent secondary antibodies (1/1000; Alexa, Molecular Probes). Cell nuclei were counterstained with Hoechst (Sigma).

*In situ* hybridization {#s2e}
-----------------------

Digoxigenin-labeled antisens RNA probes for *gad1, VGlut1* [@pone.0092113-Li1], *TH* [@pone.0092113-Parlier1], *tubb2b* [@pone.0092113-Chitnis1], *Bru* [@pone.0092113-Amato1], *dpysl3* [@pone.0092113-Souopgui1], *Ptf1a* [@pone.0092113-Afelik1] and *Ascl1* [@pone.0092113-Talikka1] were generated according to the manufacturer's instruction (Roche). Whole mount *in situ* hybridization [@pone.0092113-Parain1] and double fluorescent *in situ* hybridizations on cryosections [@pone.0092113-Lea1] were carried out as previously described.

RT-qPCR {#s2f}
-------

Stage 19 embryos were treated with cycloheximide (CHX, 10 μg/ml) during 2.5 hours. Total RNA from 8 embryos was then isolated using the Nucleospin RNA XS kit (Macherey Nagel). Reverse transcription was performed using IscriptcDNA Synthesis Kit (Biorad). RNA quality was evaluated using Experion (BioRad). qPCR reactions were performed in triplicate using SsoFast Eva green Supermix (Biorad) on a C1000 Thermal Cycler (CFX96 Real-Time System, Biorad). All values were normalized to the level of the reference gene *ornithine decarboxylase* (*ODC*) using Biorad CFX Manager Software. Primers sequences are: *tubb2b* forward 5′cccgtgccatccttgtggatttt3′, *tubb2b* reverse 5′gcccagttattgccagcaccactt3′, *Ptf1a* forward 5′gccgctcaggaaccccaaca3′, *Ptf1a* reverse 5′ggcagcccgtagtctgggtca3′, *ODC* forward 5′catggcattctccctgaagtacaagaa3′ and ODC reverse 5′ggacagtggtaggggcaagctca3′.

Western-blot analyses {#s2g}
---------------------

Total protein lysates were prepared from stage 14 embryos and submitted to western blot analysis using an anti-Myc antibody (Sigma) as previously described [@pone.0092113-Taelman1].

Image analysis and quantification {#s2h}
---------------------------------

Shown in figures are representative data from one experiment that has been performed at least in duplicate. Fluorescent staining was visualized with a M2 Zeiss microscope. Images were captured with a digital camera AxioCam MRc and AxioVision Rel 7.8 software. The quantification of *in situ* hybridization signal intensity in the eyes of whole embryos was quantified using Adobe Photoshop CS4.

Ethics statement {#s2i}
----------------

All animal procedures were conducted under the supervision of several licensed personnel, including the director of research of the CNRS and professor at the university Paris-Sud, with licenses to perform *Xenopus* experimentation (authorization 91-29 and 91-28), in accordance with French government policies. The study was conducted under an institutional license (number B 91-471-102 up to 2012 and C 91-471-102 since 2013). The study protocol was approved by the institutional animal care committee, the Direction Départementale de la Protection des Populations (license B/C 91-471-102).

Results {#s3}
=======

*Ascl1* knockdown impairs retinal GABAergic neuron genesis {#s3a}
----------------------------------------------------------

To address the potential requirement of *Ascl1* in GABAergic and glutamatergic phenotype acquisition, we performed morpholino (Mo) injections in two cell stage embryos. We examined the effect of *Ascl1* loss-of-function by analysing the expression of *gad1* (*glutamic acid decarboxylase*) and *VGlut1* (*vesicular glutamate transporter 1*), which respectively encode the rate-limiting enzyme for GABA biosynthesis and a glutamate transporter expressed in neurons. The expression of a retinal pan-neuronal marker *Bru* [@pone.0092113-Amato1] remained largely unaffected in *Ascl1*-Mo injected retinas compared to control ones (80% unaffected, n = 10 embryos; [Fig. 1A, B](#pone-0092113-g001){ref-type="fig"}), suggesting that *Ascl1* knockdown does not significantly impair neuronal commitment within the retina, as shown in the mouse [@pone.0092113-Tomita2]. *Ascl1* inhibition however caused a marked reduction of *gad1* retinal expression (100% reduced, n = 10 embryos; [Fig. 1C, D](#pone-0092113-g001){ref-type="fig"}), indicative of an impaired production of GABAergic neurons. Importantly, this was accompanied by a significant decrease in the expression of *Ptf1a* (90% reduced, n = 10 embryos; [Fig. 1E, F](#pone-0092113-g001){ref-type="fig"}), a crucial determining factor of GABAergic fate in the retina [@pone.0092113-Dullin1], [@pone.0092113-Fujitani1], [@pone.0092113-Nakhai1]. Then, we observed in *Ascl1*-Mo injected retinas that the different glutamatergic neuronal populations were unevenly affected, with *VGlut1* expression being largely unchanged in ganglion cells, reduced in the photoreceptor layer, while appearing expanded in the inner nuclear layer (INL) ([Fig. 1G, H](#pone-0092113-g001){ref-type="fig"}). Thus, in contrast to the *Ptf1a* knockdown phenotype [@pone.0092113-Dullin1], *Ascl1* morphant retinas do not exhibit an overall increase of *VGlut1* staining. As a whole, blocking Ascl1 mainly precludes commitment of precursor cells towards a GABAergic fate. However, the overall observed defects, in particular the loss of some glutamatergic cells in the outer nuclear layer, cannot be simply explained by a switch from GABAergic to glutamatergic cell types. A plausible explanation would be that part of the *Ascl1* knockdown phenotype primarily results from a loss of its proneural activity.

![*Ascl1* is required for retinal GABAergic cell genesis.\
Whole mount *in situ* hybridization on stage 35 embryos following *Ascl1* or control morpholino (Mo) injection in one blastomere at the two-cell stage. Shown for each indicated probe are representative pictures of the observed labelling in the head region (lateral views, anterior on the left) and on retinal cross sections (dorsal side up). The expression of the pan-neuronal marker *Bru* (A, B) is not affected by *Ascl1* knockdown while *gad1* and *Ptf1a* stainings are severely reduced (C-F). *VGlut1* expression (G, H) is unequally affected in the different cell layers: decreased in the photoreceptor layer (white arrow) and extended in the inner nuclear layer (white arrowhead). L: Lens. Scale bar represents 300 μm (heads) or 50 μm (sections).](pone.0092113.g001){#pone-0092113-g001}

*Ascl1* overexpression in the retina biases a subset of precursor cells towards a GABAergic destiny {#s3b}
---------------------------------------------------------------------------------------------------

To investigate in more detail *Ascl1* involvement in the specification of neurotransmitter phenotypes, we turned to a gain of function strategy using a glucocorticoid-inducible *Ascl1* construct (*Ascl1-GR*), which avoids affecting early nervous system development. We analysed the fate of *Ascl1*-overexpressing cells at stage 38. Contrasting with the *Ptf1a* gain of function, which results in a dramatic overproduction of amacrine and horizontal cells [@pone.0092113-Dullin1], *Ascl1* overexpression led to a typical neurogenic phenotype, with early born neurons being increased (ganglion cells, [Fig. 2A](#pone-0092113-g002){ref-type="fig"}) at the expense of late born cells (bipolar and Müller glial cells, data not shown). However, similarly to the *Ptf1a* phenotype, quantification of GABA-positive neurons among *Ascl1*-overexpressing cells revealed an enhanced GABAergic neuronal yield compared to the control situation ([Fig. 2B](#pone-0092113-g002){ref-type="fig"}). These supernumerary inhibitory neurons were found within the ganglion cell layer and thus probably correspond to displaced amacrine cells [@pone.0092113-Farah1]. Importantly, similar results were obtained in a clonal analysis after *in vivo* lipofection ([Fig. 2C-E](#pone-0092113-g002){ref-type="fig"}). This rules out the possibility that the *Ascl1* phenotype observed in mRNA injection experiments may be secondary to early morphogenetic defects of the retina and confirms that *Ascl1* exerts a cell-autonomous function in GABAergic cell type determination.

![*Ascl1* overexpression in the retina favours GABAergic cell genesis.\
Cell fate analysis following overexpression of the indicated construct by either mRNA injection in one blastomere at the four-cell stage and dex treatment at stage 16 (A, B; analysis at stage 38) or *in vivo* lipofection at the neurula stage (C, D; analysis at stage 41). In both cases, GFP was used as a tracer to visualize injected/transfected cells. Note that *Ascl1*, *Neurog2* and *Atoh7* lipofections all result in an increased percentage of cells in the ganglion cell layer but only *Ascl1*-overexpressing cells are biased towards a GABAergic destiny. Total number of analyzed retinas and counted cells per condition is indicated in each bar. Values are given as mean +/-- s.e.m. p\<0,001 (\*\*\*), p\<0,01 (\*\*), p\<0,05 (\*) (Student's t-test). (E) shows a typical section of stage 41 retinas lipofected with *GFP* plus *Ascl1* and immunostained with anti-GABA (red) and anti-GFP (green) antibodies. Panels on the right are higher magnifications of the dotted square delineated region. The dotted line indicates the inner plexiform layer, with the ganglion cell layer on the left and the inner nuclear layer on the right. White arrow points to a transfected GABA-positive cell within the ganglion cell layer. L: Lens. Scale bar represents 300 μm (heads) or 50 μm (sections).](pone.0092113.g002){#pone-0092113-g002}

In order to figure out whether this GABAergic inducing activity is specific to Ascl1 compared to other bHLH proteins endowed as well with neurogenic properties, we performed similar *in vivo* lipofection experiments with the *atonal*-related genes *Neurog2* and *Atoh7*. As expected from previous studies [@pone.0092113-Perron1], [@pone.0092113-Kanekar1], [@pone.0092113-Wang1], overexpression of these genes, as for *Ascl1*, resulted in an imbalanced production of early- *versus* late-born cell types ([Fig. 2C](#pone-0092113-g002){ref-type="fig"} and data not shown). However, in contrast to the *Ascl1* gain of function phenotype, the ratio of GABAergic neurons among *Neurog2* or *Atoh7* transfected cells in the ganglion cell layer did not differ from the control situation ([Fig. 2D](#pone-0092113-g002){ref-type="fig"}).

Altogether, our data highlight that, although *Ascl1* shares with *Neurog2* or *Atoh7* a neurogenic activity impacting on retinal cell type distribution, it has the specific ability to bias a subset of progenitors towards a GABAergic fate.

Ascl1 has a specific GABAergic inducing activity and is epistatic to glutamatergic factors {#s3c}
------------------------------------------------------------------------------------------

It has previously been shown that *Ascl1, Neurog2*, *NeuroD1, Atoh7* and *Ptf1a* are all sufficient to induce ectopic neurogenesis when overexpressed in the epidermis of *Xenopus* embryos [@pone.0092113-Kanekar1], [@pone.0092113-Talikka1], [@pone.0092113-Lee1], [@pone.0092113-Ma1], [@pone.0092113-Rupp1], [@pone.0092113-Turner1]. To further assess the functional specificity of *Ascl1* as a GABAergic inducing factor, we injected the corresponding mRNA as well as those encoding the aforementioned bHLH factors and compared the neurotransmitter phenotypes they induced in ectopic neurons formed within the epidermis. As expected, each of them induced ectopic *tubb2b* (previously called *N-tubulin*) expression in stage 24 embryos ([Fig. 3A](#pone-0092113-g003){ref-type="fig"}). Except for *Ascl1*, this was associated with a robust *VGlut1* staining ([Fig. 3A, B](#pone-0092113-g003){ref-type="fig"}). Only *Ptf1a* and *Ascl1* were able to promote ectopic *gad1* expression ([Fig. 3A, C](#pone-0092113-g003){ref-type="fig"}). We therefore conclude that *Ascl1* has the unique property among these factors, to convert presumptive epidermal cells into GABAergic neurons without simultaneously inducing glutamatergic ones.

![Comparison of GABAergic and glutamatergic inducing activities of five different bHLH factors.\
Whole mount *in situ* hybridization analyses of *tubb2b, VGlut1* or *gad1* expression on stage 24 embryos injected with the indicated mRNAs in one blastomere at the two-cell stage. (A) Arrows indicate ectopic expression in the epidermis (anterior on the left, dorsal side up). All the tested bHLH factors exhibit neurogenic activity, as inferred from *tubb2b* ectopic expression. However, only *Ascl1* specifically induces *gad1* ^+^ neurons without inducing *VGlut1* ^+^ ones. (B, C) Quantification of embryos displaying *VGlut1* (B) or *gad1* (C) ectopic expression. *Ascl1* interferes with *Ptf1a*-, *Neurog2*-, *NeuroD1*- and *Atoh7*-dependent production of *VGlut1* ^+^ neurons, while none of these factors affect *Ascl1* GABAergic inducing activity. (D) Quantification of embryos with weak or strong ectopic *gad1* staining following mRNA injection of *Ascl1* alone or together with *Neurog2*. Note that *Neurog2* enhances *Ascl1* GABAergic inducing activity. Total number of analyzed embryos per condition is indicated in each bar. Error bars represent 95% confidence intervals. p\<0,001 (\*\*\*), p\<0,01 (\*\*), p\<0,05 (\*) (binomial test). Scale bar represents 500 μm.](pone.0092113.g003){#pone-0092113-g003}

We next wondered whether Ascl1 might act as an inhibitor of glutamatergic neuron genesis and thus investigated the genetic relationships between *Ascl1* and the other bHLH genes, in co-injection experiments. The glutamatergic inducing activities of *Neurog2*, *NeuroD1, Atoh7* and *Ptf1a* were all dramatically reduced upon *Ascl1* misexpression ([Fig. 3A, B](#pone-0092113-g003){ref-type="fig"}), indicating that Ascl1 indeed actively represses the glutamatergic fate of ectopically produced neurons. In contrast, neither *Neurog2*, *NeuroD1* or *Atoh7* were able to interfere with the *Ascl1*-dependent induction of GABAergic neurons ([Fig. 3A, C](#pone-0092113-g003){ref-type="fig"}). Surprisingly, we found that embryos overexpressing both *Ascl1* and *Neurog2* displayed more ectopic *gad1*-positive cells compared to embryos injected with *Ascl1* alone ([Fig. 3D](#pone-0092113-g003){ref-type="fig"}), suggesting an unexpected synergistic effect. Altogether, these data demonstrate that, in this ectopic context, *Ascl1* is epitastic to these various bHLH genes. In the retina as well, overexpression of *Ascl1* together with *Neurog2* still resulted in an increased production of GABAergic cells within the ganglion cell layer ([Fig. 4A, B](#pone-0092113-g004){ref-type="fig"}). However, no synergy was observed in this context.

![*Ascl1* overexpression together with *Neurog2* still promotes production of GABAergic cells in the retina.\
(A) Stage 41 retinal sections immunostained with anti-GABA (red) and anti-GFP (green) antibodies. Embryos were injected with the indicated mRNAs in one blastomere at the four-cell stage and treated with dexamethasone at stage 16. Panels on the right are higher magnifications of the dotted square delineated region. The dotted line indicates the inner plexiform layer. Arrowheads point to GFP/GABA-positive cells within the ganglion cell layer. (B) Quantification of GABAergic cell proportion among GFP^+^ cells in the ganglion cell layer, showing that Ascl1 GABAergic inducing activity is not affected by *Neurog2* misexpression. Total number of analyzed retinas and counted cells per condition is indicated in each bar. p\<0,05 (\*) (Student's t-test). Values are given +/-- s.e.m. L: Lens. Scale bar represents 50 μm.](pone.0092113.g004){#pone-0092113-g004}

*Ascl1* catecholaminergic inducing activity is impaired by glutamatergic factors {#s3d}
--------------------------------------------------------------------------------

As recently shown, *Ascl1* misexpression in the epidermis also leads to the ectopic generation of catecholaminergic neurons [@pone.0092113-Parlier1], authenticated by the expression of *tyrosine hydroxylase* (*TH*). We thus decided to pursue our comparative study by monitoring *TH* labelling after *Ascl1*, *Neurog2*, *NeuroD1*, *Atoh7* or *Ptf1a* mRNA injection. In contrast to *Ascl1*, none of these genes were able to promote the production of *TH*-positive neurons, emphasizing again the specific role of *Ascl1* in neuronal subtype determination ([Fig. 5A](#pone-0092113-g005){ref-type="fig"}). Epistatic analyses revealed that the proportion of embryos displaying ectopic *TH* expression was slightly decreased upon co-injection of *Ascl1* with either *Atoh7* or *NeuroD1*, although this was not statistically significant. It was however significantly reduced when *Ascl1* was misexpressed together with *Neurog2* or *Ptf1a*, suggesting that these two genes could interfere with the *Ascl1* catecholaminergic inducing activity ([Fig. 5A, B](#pone-0092113-g005){ref-type="fig"}). Such a result contrasts with the interaction previously demonstrated for the induction of GABAergic neurons and reflects that the same set of transcription factors establishes variable genetic interactions within distinct differentiation pathways.

![Comparison of the catecholaminergic inducing activities of five different bHLH factors.\
(A) Whole mount *in situ* hybridization analysis of *Tyrosine Hydroxylase (TH)* expression on stage 24 embryos injected with the indicated mRNAs in one blastomere at the two-cell stage (anterior on the left, dorsal side up). Arrowheads indicate the position of previously described *TH*-positive antero-ventral neurons [@pone.0092113-Parlier1], while arrows point to ectopic *TH* staining. Note that, among all tested bHLH factors, only *Ascl1* induces ectopic *TH* expression. Sibling embryos were also hybridized with the *tubb2b* probe as a positive control (see [Figure 3A](#pone-0092113-g003){ref-type="fig"}). (B) Quantification of embryos displaying ectopic *TH^+^* neurons, showing that *Neurog2* and *Ptf1a* significantly reduce the catecholaminergic inducing activity of *Ascl1*. Total number of analyzed embryos per condition is indicated in each bar. Error bars represent 95% confidence intervals. p\<0,05 (\*) (binomial test). Scale bar represents 500 μm.](pone.0092113.g005){#pone-0092113-g005}

The GABAergic and catecholaminergic inducing activities of Ascl1 are conferred by its basic domain {#s3e}
--------------------------------------------------------------------------------------------------

We next examined which Ascl1 domains account for the protein activity in neuronal subtype specification. We used a series of chimeric *Ascl1:Neurog2* constructs ([Fig. 6A](#pone-0092113-g006){ref-type="fig"}) with interchanged basic and/or HLH domains (DNA binding and dimerization domain, respectively) and tested their ability to induce *TH*, *gad1* and *VGlut1* ectopic expression. Importantly, the chimeric proteins were properly expressed following mRNA injection ([Fig. 6B](#pone-0092113-g006){ref-type="fig"}) and all but one (A~H~N) retained a neurogenic activity, as inferred by their ability to promote the expression of the pan-neuronal marker *dpysl3* (previously called *CRMP4*; [Fig. 6A, C](#pone-0092113-g006){ref-type="fig"}). Noticeably, swapping the entire bHLH domains of Ascl1 and Neurog2 was sufficient to invert their respective properties in neurotransmitter phenotype induction. The Neurog2 protein containing the Ascl1 bHLH indeed converted into a GABAergic and catecholaminergic neuron inducer, while the Ascl1 protein with the Neurog2 bHLH turned into a glutamatergic one ([Fig. 6A, C](#pone-0092113-g006){ref-type="fig"}; compare A~bHLH~N to Ascl1 and N~bHLH~A to Neurog2). This demonstrates that the functional specificity of these two proteins resides in their respective bHLH domains. In addition, we found that the presence of the Ascl1 basic domain in chimeric constructs was necessary and sufficient to trigger *TH* and *gad1* ectopic expression ([Fig. 6A, C](#pone-0092113-g006){ref-type="fig"}; compare A~b~N and N~H~A to N~b~A for *gad1* and *TH* staining). Conversely, only the chimeric proteins containing the Neurog2 HLH domain had the ability to induce glutamatergic neurons ([Fig. 6A, C](#pone-0092113-g006){ref-type="fig"}; see *VGlut1* labelling for A~b~N and N~H~A *versus* N~b~A). In line with this observation, the two chimeric proteins containing both the basic domain of Ascl1 and the HLH of Neurog2 (A~b~N and N~H~A proteins) were able to simultaneously promote *gad1*, *TH* and *VGlut1* expression. Altogether, these results suggest that the functional specificities of Ascl1 and Neurog2 in neurotransmitter subtype specification do not reside in the same protein domain. GABAergic and catecholaminergic inducing activity of Ascl1 primarily relies on its basic domain while glutamatergic inducing activity of Neurog2 is imparted by its HLH domain.

![Mapping of Ascl1 and Neurog2 domains accounting for their functional specificity in neuronal subtype specification.\
(A) bHLH protein sequences of the Myc-tagged inducible Ascl1:Neurog2 chimeric constructs used in B and C. Ascl1 and Neurog2 sequences are depicted in red and black, respectively. Shown on the right and illustrated in (C) is the ability of the different proteins to induce *dpysl3*, *VGlut1, gad1* or *TH.* Percentages of embryos with ectopic expression are indicated. (B, C) Embryos were injected in one blastomere at the four-cell stage with the indicated wild-type or chimeric mRNA and dexamethasone was added at stage 13. (B) Western-blot using an anti-Myc antibody showing that each chimeric protein has been produced. Detection of GAPDH serves as a loading control. (C) Whole mount *in situ* hybridization analyses of *dpysl3*, *VGlut1, gad1* or *TH* expression on stage 22 or 28 injected embryos (anterior on the right, dorsal side up). Altogether, these domain-swapping experiments show that the GABAergic inducing activity of Ascl1 resides in its basic domain, while the glutamatergic inducing activity of Neurog2 is imparted by its HLH domain. In each panel the number of analysed embryos is indicated. Scale bar represents 250 μm.](pone.0092113.g006){#pone-0092113-g006}

To assess whether this also holds true within the retina, we overexpressed the chimeric construct *A~b~N* by *in vivo* lipofection ([Fig. 7A](#pone-0092113-g007){ref-type="fig"}). Similarly to wild-type *Ascl1*, *A~b~N* transfection increased the proportion of cells within the ganglion cell layer ([Fig. 7B](#pone-0092113-g007){ref-type="fig"}) and biased these additional neurons towards a GABAergic destiny ([Fig. 7C](#pone-0092113-g007){ref-type="fig"}). This indicates that Ascl1 basic domain is sufficient to drive a subset of retinal progenitor cells towards a GABAergic fate in the retina.

![Retinal GABAergic inducing activity of Ascl1 resides in its basic domain.\
(A) Stage 41 retinal sections immunostained with anti-GABA (red) and anti-GFP (green) antibodies. Embryos were lipofected with *Ascl1* or the inducible *A~B~N* chimeric construct (encoding a Neurog2 protein with the basic domain of AsclI). Dexamethasone was added immediately after lipofection at stage 18. Panels on the right are higher magnifications of the dotted square delineated region. The dotted line indicates the inner plexiform layer. Arrowheads indicate GABA^+^/GFP^+^ cells within the ganglion cell layer. (B-C) Quantification of GFP^+^ cells and GABA^+^/GFP^+^ in the ganglion cell layer showing that similarly to *Ascl1*, *A~B~N* increases the percentage of cells in the ganglion cell layer but also biases these cells towards a GABAergic destiny. Total number of analyzed retinas and counted cells per condition is indicated in each bar. Values are given as mean +/-- s.e.m. p\<0,01 (\*\*), p\<0,05 (\*) (Student's t-test). L: Lens. Scale bar represents 50 μm.](pone.0092113.g007){#pone-0092113-g007}

*Phox2a* and *Hand2* are essential downstream components of Ascl1 catecholaminergic pathway but are dispensable for its GABAergic inducing activity {#s3f}
---------------------------------------------------------------------------------------------------------------------------------------------------

The DNA binding basic domain of Ascl1 being central to its activity, we next sought to identify potential transcriptional targets involved in its GABAergic *versus* catecholaminergic inducing activity. The homeodomain Phox2a and bHLH Hand2 proteins act downstream Ascl1 for the determination and differentiation of noradrenergic neurons [@pone.0092113-Goridis1], [@pone.0092113-Howard1], [@pone.0092113-Lo1], [@pone.0092113-Morikawa1]. To examine whether these genes may also be involved in Ascl1 GABAergic inducing activity, we simultaneously misexpressed *Ascl1* while knocking down both *Phox2a* and *Hand2* using specific morpholinos. As previously described, this resulted in a significantly decreased proportion of embryos exhibiting ectopic *TH* staining. In contrast, the ability of Ascl1 to induce *gad1*-positive neurons appeared largely unaffected ([Fig. 8A, B](#pone-0092113-g008){ref-type="fig"}). This demonstrates that *Phox2a* and *Hand2*, although required for Ascl1-dependent production of catecholaminergic neurons, are dispensable for its GABAergic inducing activity.

![Distinct transcriptional networks sustain *Ascl1* GABAergic and catecholaminergic inducing activities.\
Whole mount *in situ* hybridization analyses of *TH* or *gad1* expression on stage 24 embryos following injection of mRNA and/or morpholinos (Mo), as indicated, in one blastomere at the two-cell stage. (A, C) Arrows point to ectopic *TH* or *gad1* expression (anterior on the left, dorsal side up). Sibling embryos were also hybridized with the *tubb2b* probe as a positive control (data not shown). (B, D) Quantification of embryos displaying ectopic *TH* or *gad1* expression. Note that *Phox2a* and *Hand2* knockdown significantly reduces Ascl1 ability to induce *TH* expression but does not impair its GABAergic inducing activity (B), which specifically depends on *Ptf1a* (D). Total number of analyzed embryos per condition is indicated in each bar. Error bars represent 95% confidence intervals. P\<0,001 (\*\*\*), p\<0,01 (\*\*) (binomial test). Scale bar represents 500 μm.](pone.0092113.g008){#pone-0092113-g008}

*Ptf1a* is required for Ascl1 GABAergic inducing activity as a direct transcriptional target {#s3g}
--------------------------------------------------------------------------------------------

Since both *Ascl1* and *Ptf1a* share the ability to induce ectopic GABAergic neurons, in contrast to the other tested bHLH genes ([Fig. 3](#pone-0092113-g003){ref-type="fig"}), we next investigated whether they could act in the same transcriptional network. We first examined *Ptf1a* requirement for Ascl1 GABAergic and catecholaminergic inducing activities by simultaneously overexpressing *Ascl1* and knocking down *Ptf1a* ([Fig. 8C, D](#pone-0092113-g008){ref-type="fig"}). The *Ascl1*-dependent ectopic *TH* expression was unaffected by *Ptf1a* inhibition, showing that this gene is dispensable for Ascl1 catecholaminergic inducing activity. In contrast, the percentage of embryos displaying ectopic *gad1* staining was significantly decreased by the concomitant blockade of *Ptf1a*. These results indicate that *Ptf1a* acts downstream *Ascl1* for the generation of ectopic GABAergic neurons.

We then tested whether this *Ptf1a* dependency might rely on a transcriptional interaction. We found that *Ascl1* mRNA injection promoted *Ptf1a* ectopic expression in the epidermis ([Fig. 9A, B](#pone-0092113-g009){ref-type="fig"}). In contrast, *Neurog2* misexpression was unable to do so. Together, these data suggest the existence of a positive transcriptional regulation exerted by Ascl1 on *Ptf1a*. We thus investigated whether *Ptf1a* could constitute a direct target of Ascl1. In this purpose, we performed gene induction assays on *Ascl1-GR* injected embryos in the absence of protein synthesis, using the translation-blocking drug cycloheximide (CHX). In the absence of CHX, *Ascl1* overexpression lead to a strong increase of both *tubb2b* and *Ptf1a* expression level, as assayed by RT-qPCR analysis ([Fig. 9C](#pone-0092113-g009){ref-type="fig"}). Only *Ptf1a* up-regulation persisted upon CHX treatment, consistent with *Ptf1a* being a direct Ascl1 target gene ([Fig. 9D](#pone-0092113-g009){ref-type="fig"}).

![*Ptf1a* is a direct transcriptional target of *Ascl1*.\
(A) Whole mount *in situ* hybridization analyses of *Ptf1a* expression on stage 22 embryos injected with *Ascl1* or *Neurog2* mRNA in one blastomere at the two-cell stage. Note that Ascl1 is able to activate *Ptf1a* expression in the epidermis (arrow). Sibling embryos were also hybridized with the *tubb2b* probe as a positive control (data not shown). (B) Quantification of embryos displaying *Ptf1a* ectopic expression. Total number of analysed embryos per condition is indicated in each bar. Error bars represent 95% confidence intervals. P\<0,001 (\*\*\*) (binomial test). (C, D) RT-qPCR analyses of *tubb2b* and *Ptf1a* expression in embryos injected with *Ascl1-GR* at the two-cell stage and treated with dexamethasone (dex) and/or cycloheximide (CHX) from stage 19 to stage 21. Note that *Ptf1a* up-regulation upon dex treatment is maintained in the presence of CHX. Scale bar represents 500 μm.](pone.0092113.g009){#pone-0092113-g009}

In order to know whether such transcriptional interaction could also hold true in the retina, we first carefully compared their expression pattern during retinogenesis ([Fig. 10](#pone-0092113-g010){ref-type="fig"}). Consistent with a *Ptf1a*-independent proneural function, we found that *Ascl1* was broadly expressed in early retinal precursors prior to the onset of *Ptf1a* expression. However, from stage 30 onwards, regions of overlapping expression were clearly observed in the neural retina of the optic cup and then within the neurogenic zone of the mature retina called the ciliary marginal zone (CMZ) [@pone.0092113-Perron2]. We next asked whether *Ptf1a* overexpression could rescue *Ascl1* knockdown. We found indeed that *gad1* expression was restored to a control level in the retina of *Ascl1* morphant embryos overexpressing *Ptf1a* ([Fig. 11](#pone-0092113-g011){ref-type="fig"}). Altogether, these results are consistent with *Ascl*1 acting upstream *Ptf1a* in the transcriptional network controlling GABAergic neuron genesis in the retina.

![Comparison of *Ascl1* and *Ptf1a* expression patterns during retinogenesis.\
(A, B) Whole mount *in situ* hybridization analysis of *Ascl1* and *Ptf1a* expression during retinogenesis. Shown are representative pictures of the observed labelling in the head region (A; lateral views, anterior on the left) and on retinal cross sections (B; dorsal side up). *Ascl1* and *Ptf1a* are expressed in overlapping domains of the neural retina at stage 30 and in the ciliary marginal zone (CMZ, delineated by doted line) from stage 35 onwards. (C) Double fluorescent *in situ* hybridization against *Ptf1a* (green) and *Ascl1* (red) performed on stage 40 retinal sections. *Ascl1* staining in the CMZ is delineated by a white doted line. Panel on the right shows a magnification of the dorsal CMZ. Neither *Ascl1* nor *Ptf1a* are detected in zone 1 (stem cell compartment). In zone 2 (early progenitors), only *Ascl1* is expressed. The expression patterns of both genes overlap in zone 3 (late progenitors; yellow doted line). In zone 4 (postmitotic retinoblasts), *Ascl1* expression vanishes while that of *Ptf1a* persists. OP: Optic vesicle, L: Lens. Scale bar represents 300 μm (A) or 50 μm (B, C).](pone.0092113.g010){#pone-0092113-g010}

![*Ptf1a* overexpression rescues *Ascl1* knockdown in the retina.\
(A) Whole mount *in situ* hybridization analysis of *gad 1* expression at stage 37. Embryos were injected with the indicated mRNAs and/or morpholinos (Mo) in two blastomeres at the two-cell stage and treated with dexamethasone at stage 22. Shown are representative pictures of the observed labelling in the head region (lateral views, anterior on the left) and on retinal sections (dorsal side up). (B) Quantification of *gad1* staining intensity in the eye of injected embryos. Results are presented as percentage increase/decrease relative to the average intensity found in controls. Total number of analyzed embryos per condition is indicated in each bar. Values are given as mean +/-- s.e.m. p\<0,001 (\*\*\*) (Student's t-test); N.S. : Non significant; L: Lens. Scale bar represents 300 μm (heads) or 50 μm (sections).](pone.0092113.g011){#pone-0092113-g011}

Discussion {#s4}
==========

The molecular bases underlying neurotransmitter subtype determination in the retina remain largely unexplored. As previously shown in the brain and peripheral nervous system [@pone.0092113-Parras1], [@pone.0092113-Pattyn1], [@pone.0092113-Hirsch1], [@pone.0092113-Lo1], our data suggest that during retinogenesis, Ascl1 does not simply act as a proneural factor committing progenitor cells to a generic neuronal fate, but also contributes to the specification of their neurotransmitter identity. We showed indeed that Ascl1 is required for retinal GABAergic cell type genesis and sufficient to redirect a subpopulation of progenitors towards this inhibitory neuronal destiny. Besides, taking advantage of an *in vivo* neurogenic assay in the *Xenopus* epidermis, we found that Ascl1 GABAergic determining activity is instructive, as inferred by its ability to counteract glutamatergic differentiation programs. Finally, we gained insights into downstream genetic networks underlying Ascl1 functions in neurotransmitter subtype specification by showing that its GABAergic activity involves the direct transcriptional regulation of *Ptf1a* ([Fig. 12](#pone-0092113-g012){ref-type="fig"}).

![Summary of *Ascl1* genetic network in neuronal subtype specification.\
Green, red and blue arrows point to neuronal subtypes induced by *Neurog2* and *Ascl1*. Identified downstream components required for their respective activities are indicated. Grey arrows illustrate epistatic relationships between *Neurog2* and *Ascl1*, as suggested by our results. Protein domains in red confer to Ascl1 and Neurog2 their specific GABAergic/catecholaminergic and glutamatergic activities, respectively (see text for more details).](pone.0092113.g012){#pone-0092113-g012}

Ascl1 GABAergic determining activity in the retina {#s4a}
--------------------------------------------------

Most *Ascl1* gain and loss of function analyses in the retina have so far uncovered phenotypes predominantly related to its proneural activity. *Ascl1* has indeed been shown to be required for neuronal *versus* glial fate decisions during late neurogenesis [@pone.0092113-Nelson1], [@pone.0092113-Tomita1], [@pone.0092113-Tomita2], [@pone.0092113-Hatakeyama2] and to participate, with other proneural genes, to the spatiotemporal progression of the neurogenic wave in the retina [@pone.0092113-Hufnagel1]. In line with this, recent lineage experiments in mouse revealed that *Ascl1*-expressing progenitors contribute to all major cell types of the retina with the exception of ganglion cells [@pone.0092113-Brzezinski1]. Such a primary function in determining a generic neuronal program has thus hindered the identification of its potential specific activity in retinal cell subtype specification. In line with this, overexpression of *Ascl1* or other bHLH genes such as *Neurog2* or *Atoh7* results in apparently similar cell type distribution defects within the *Xenopus* retina [@pone.0092113-Perron1], [@pone.0092113-Kanekar1], [@pone.0092113-Ohnuma1], [@pone.0092113-Wang1]. In the present manuscript, we revealed that Ascl1 is actually endowed with a GABAergic determining function that superimposes to its proneural activity. Of note, neither *Neurog2* nor *Atoh7* exhibit this property. Importantly, our results are consistent with a previous study in chick reporting that, unlike *Neurog2*, *NeuroD1* or *Atoh7*, *Ascl1* misexpression promotes an overproduction of amacrine cells, the major retinal GABAergic cell type [@pone.0092113-Mao1]. Therefore, we propose that Ascl1 not only promotes neurogenesis but also biases, in combination with other bHLH factors (see below), a subset of precursor cells towards particular neurotransmitter subtypes, thereby contributing to neuronal diversity during retinogenesis.

Epistatic relationships of bHLH genes in neuronal subtype specification {#s4b}
-----------------------------------------------------------------------

The strong context-dependency of Ascl1 function in neurotransmitter subtype specification relies on the presence of other regionally expressed transcription factors including bHLH ones [@pone.0092113-Powell1]. In line with this, our data show that Ascl1 ability to induce ectopic catecholaminergic neurons is impaired in the presence of Neurog2, NeuroD1 or Atoh7. In contrast, its GABAergic inducing activity is not counteracted by these factors, both ectopically and in retinal progenitors. Thus Ascl1 likely exerts an instructive role in promoting GABAergic cell fate as previously proposed in the ventral telencephalon [@pone.0092113-Fode1], [@pone.0092113-Parras1].

Unexpectedly, *Ascl1*-dependent ectopic GABAergic neuron production was found to be enhanced by *Neurog2* co-expression. This suggests that, in the few locations where both factors are co-expressed in the same cells [@pone.0092113-Brzezinski1], [@pone.0092113-Kele1], [@pone.0092113-Mizuguchi2], [@pone.0092113-Roybon1], they might act synergistically or at least cooperate within neuronal subtype specification programs. This could be the case in the retina where, although the *Ascl1* and *Neurog2* lineages are largely distinct, such progenitors expressing both genes have recently been described [@pone.0092113-Brzezinski1]. Interestingly, *Neurog2* was identified as a direct transcriptional target of *Ptf1a* in the chick dorsal spinal cord and cerebellum [@pone.0092113-Henke1], two regions where *Ptf1a*, *Ascl1* and *Neurog2* expressions partially overlap [@pone.0092113-Zordan1]. *Neurog2* might thus participate within these domains in the *Ascl1*/*Ptf1a*-dependent GABAergic program. Additionally, Ascl1 and Neurog2 were shown to heterodimerize and function in common transcriptional complexes [@pone.0092113-Henke1], [@pone.0092113-Gradwohl1], [@pone.0092113-Henke2]. Investigating *Ascl1* interactions with other expressed bHLH genes in the retina will surely help understand the combinatorial codes governing neurotransmitter subtype determination.

Functional domain and transcriptional network of Ascl1 involved in GABAergic cell determination {#s4c}
-----------------------------------------------------------------------------------------------

Previous reports proposed that the HLH domain of murine Ascl1 contains the information underlying its specific activity in neuronal subtype specification [@pone.0092113-Park1], [@pone.0092113-Nakada1]. In particular, a study using chimeric and mutated constructs concluded that Ascl1-mediated acquisition of GABAergic identity in forebrain precursor cultures does not occur through DNA binding, but rather through HLH domain protein-protein interactions [@pone.0092113-Jo1]. The authors however raised the possibility that, in their assays, alterations of endogenous *Ascl1* expression may have interfered with proper GABAergic differentiation. Our domain swapping experiments led to an opposite conclusion, highlighting the essential role of Ascl1 basic domain in both its catecholaminergic and GABAergic inducing activities. Interestingly, the same was not true for Neurog2, whose ability to induce glutamatergic neurons was found to be imparted by its HLH domain. Although we cannot exclude that Ascl1 or Neurog2 might act through different molecular mechanisms depending on the cellular context, our data suggest that distinct domains within these bHLH factors mediate their functional specificities in neurotransmitter phenotype specification.

We showed that Ascl1 exerts its GABAergic and catecholaminergic determining activities by controlling distinct genetic cascades involving *Ptf1a* and *Phox2a*/*Hand2*, respectively. We found in particular that Ascl1 ability to promote *gad1*-positive neurons requires *Ptf1a*. Additionally, Ascl1 was able to activate *Ptf1a* transcription and to be necessary for its retinal expression. In line with such a positive transcriptional regulation, previous data showed that *Ascl1* is required for the induction and/or maintenance of *Ptf1a* during the late phase of dorsal sensory interneuron development [@pone.0092113-Mizuguchi1], [@pone.0092113-Meredith1]. Moreover, we provide some evidence that *Ptf1a* might constitute a direct transcriptional target of Ascl1. Consensus binding sites for Ascl1 have previously been described in two conserved *Ptf1a* enhancer regions but have not proved to be functional [@pone.0092113-Meredith1]. Additional Ascl1 binding sites may however lie in other *Ptf1a* regulatory regions.

Altogether, our work demonstrated for the first time a role for Ascl1 in the generation of GABAergic interneurons in the retina and provided insights into the regulatory circuits responsible for its activity in neurotransmitter subtype specification.
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